Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dalfampridine
Drug ID BADD_D00574
Description Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indications and Usage Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Marketing Status Prescription
ATC Code N07XX07
DrugBank ID DB06637
KEGG ID D04127
MeSH ID D015761
PubChem ID 1727
TTD Drug ID D08YIN
NDC Product Code 38779-3205; 42571-338; 63190-0510; 46016-5042; 16729-292; 56125-427; 62756-429; 0054-0479; 42571-275; 51927-5030; 12817-054; 54382-125; 62756-038; 63190-0530; 51407-246; 65862-917; 65372-1157; 65862-863; 62991-3143; 67877-444; 10144-427; 0378-0509
Synonyms 4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR
Chemical Information
Molecular Formula C5H6N2
CAS Registry Number 504-24-5
SMILES C1=CN=CC=C1N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chills15.05.03.016; 08.01.09.0010.018300%
Choking22.02.05.0010.003921%Not Available
Cholelithiasis09.03.01.0020.006536%Not Available
Chromaturia20.02.01.0020.011764%
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Clostridium difficile colitis11.02.02.004; 07.19.01.0040.002614%Not Available
Cold sweat23.02.03.002; 08.01.03.0240.005229%Not Available
Colitis07.08.01.001--
Colitis ulcerative10.02.01.004; 07.08.01.0050.003921%Not Available
Concussion17.11.01.004; 12.01.10.0050.007843%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctival haemorrhage24.07.05.001; 06.07.01.0010.002614%Not Available
Conjunctivitis11.01.06.012; 06.04.01.0020.003921%
Constipation07.02.02.0010.073201%
Coordination abnormal17.02.02.0040.009150%Not Available
Coronary artery occlusion24.04.04.013; 02.02.01.0060.002614%Not Available
Cough22.02.03.001--
Creatinine renal clearance decreased13.13.01.0130.005229%Not Available
Crohn's disease10.02.01.005; 07.08.01.015--Not Available
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.005--Not Available
Crystal urine present13.13.02.0150.002614%Not Available
Cyst16.02.02.002; 08.03.05.0010.003921%Not Available
Cystitis20.03.02.002; 11.01.14.0010.027450%
Death08.04.01.001--
Decreased interest19.15.02.0040.002614%Not Available
Decubitus ulcer23.03.11.0060.003921%Not Available
Dehydration14.05.05.001--
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.001--Not Available
Depressed mood19.15.02.0010.010457%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 20 Pages